Coley expands CpG product discovery
Coley Pharmaceutical Group has started operations at its new research facility in Langenfeld, Germany. The laboratory provides increased space for the company's current immunology, molecular biology and biochemistry departments as well as its European clinical, regulatory and administrative functions.
More importantly, Langenfeld will be the home of Coley's human cell screening drug discovery platform, a proprietary product for the rapid generation and characterisation of potential CpG therapeutics.
Coley also recently expanded its Ottawa, Canada, facility, with activities in clinical operations, regulatory affairs and clinical chemistry with preclinical research.
Since the company's founding in 1997, Coley's research programmes in the US, Germany and Canada have supported nine ongoing clinical trials and four CpG based drugs in development.
The company expects the new Lagenfeld facility will further build on its rapid progress and productivity in the near future.